Modern therapy of acute lymphoblastic leukemia.

  title={Modern therapy of acute lymphoblastic leukemia.},
  author={Renato Bassan and Dieter Hoelzer},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={29 5},
  • R. BassanD. Hoelzer
  • Published 10 February 2011
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Although acute lymphoblastic leukemia is curable in one third of adult patients, results vary greatly on account of different clinical, immunologic, and cytogenetic/genetic characteristics. These data, along with the kinetics of response to early treatment, help establish the individual risk class with considerable accuracy, and support risk-specific treatments that should warrant optimal results with as little as possible nonrelapse mortality. Modern first-line therapy consists of standard… 

Tables from this paper

Prognostic impact of minimal residual disease in adult acute lymphoblastic leukemia

This optimized risk-adapted strategy allows to spare transplant-associated morbidity and mortality in patients curable by chemotherapy in patients with inadequate MRD response to chemotherapy only in MRD responsive ones.

Prognostic Significance and Treatment Implications of Minimal Residual Disease Studies in Philadelphia-Negative Adult Acute Lymphoblastic Leukemia

Because substantial therapeutic advancement is now being achieved using intensified pediatric-type regimens, MRD analysis is especially useful to orientate stem cell transplantation choices and is progressively leading to greater than 50% cure rates.

Advances in acute lymphoblastic leukemia in adults

  • J. Ribera
  • Medicine, Biology
    Current opinion in oncology
  • 2011
Changes in adult acute lymphoblastic leukemia are improving long-term outcome, which in ongoing studies is expected to be of close to 50%, and are opening the door for future therapeutic advances.

Acute Lymphoblastic Leukemia of Adulthood: Progress or Not?

  • P. Wiernik
  • Medicine
    Current treatment options in oncology
  • 2011
There are no prospective, randomized studies that clearly demonstrate that anthracyclines, cyclophosphamide or cytarabine are required for optimal results in this leukemia, and the question arises whether current treatment may be unnecessarily intensive.

The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies

Several emerging therapies, including antibody–drug conjugates, bi-specific engagers, and chimeric antigen receptor (CAR) T cells, have demonstrated much promise and are either incorporated into the existing therapeutic paradigms or being actively investigated to improve outcomes.

TP53 in adult acute lymphoblastic leukemia

TP53 alterations should be considered in the diagnostic work-up to identify high risk ALL patients in need of intensive treatment strategies or eligible for new innovative targeted therapies.

Therapeutic developments in acute lymphoblastic leukemia

The current research in ALL focuses on the development of monoclonal antibodies and small molecule inhibitors, as well as increasing sensitivity in monitoring minimal residual disease, improving upon current chemotherapy, and improving stem cell transplantation.

Insights of Acute Lymphoblastic Leukemia with Development of Genomic Investigation.

The landscape identification of ALL genetic alterations provided the opportunity to increase the survival rate and especially minimize the relapse risk of ALL, and the importance of the development of new technologies of genomic investigation for translational medicine is highlighted.

New Approaches to the Management of Adult Acute Lymphoblastic Leukemia.

Evidence supporting the increasing role of the new therapeutic tools and treatment options in different disease subgroups, including frontline and relapsed or refractory disease, is examined.

Minimal Residual Disease Monitoring in Adult ALL to Determine Therapy

Only the patients with an unfavorable MRD response are preferably selected for allogeneic stem cell transplantation, irrespective of their clinical risk class, which spares transplant-related toxicities to MRD responsive cases.



Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.

  • F. HuguetT. Leguay H. Dombret
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
It is suggested that pediatric-inspired therapy markedly improves the outcome of adult patients with ALL, at least until the age of 45 years, as compared with the previous LALA-94 experience.

Improved outcome in adult B-cell acute lymphoblastic leukemia.

It is concluded that this short intensive therapy with six cycles is effective in adult B-ALL and the probability of leukemia free survival (LFS) is increased from 0% to 50% and 71% and the overall survival rates were greatly improved.

Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups.

The intended strategy was applicable to the majority of study patients, confirming the value of anthracyclines in SR class and, preliminarily, the usefulness of a T(lin)-specific treatment.

Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study.

PDN pretreatment response proved to be a powerful factor predicting disease outcome in adult ALL patients, and the addition of cyclophosphamide in induction significantly influenced CR achievement in a multivariate analysis.

Line Treatment of Adult Ph plus Acute Lymphoblastic Leukemia (ALL) Patients. Final Results of the GIMEMA LAL1205 Study

The primary objective of the study was to assess the activity of dasatinib in de novo adult Ph+ ALL patients in terms of complete hematological remission (CHR); the secondary objectives were treatment toxicity, rate of immunophenotypic and molecular responses, disease-free survival (DFS), relapse rate and overall survival (OS).

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review.

  • T. HahnD. Wall P. McCarthy
  • Medicine
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2006

Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol.

This study shows that elderly Ph(+) patients with ALL-often considered eligible only for palliative treatment strategies-may benefit from an imatinib-steroids protocol, which does not require chemotherapy nor a long hospitalization, is feasible, highly active, and associated with a good quality of life.

Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study

The use of imatinib in elderly patients with Ph+ ALL is very likely to improve outcome, including OS.

Central nervous system recurrence in adult patients with acute lymphoblastic leukemia

The frequency of CNS recurrence in adult patients with ALL who do not receive radiotherapy for CNS prophylaxis was similar to the frequency observed in protocols that included cranial irradiation.